Renal Tubular Acidosis (RTA) - Pipeline Insight, 2024

This “Renal tubular acidosis (RTA) - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Renal tubular acidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Renal tubular acidosis Understanding

Renal tubular acidosis (RTA): Overview

Renal tubular acidosis (RTA) is a disease that occurs when the kidneys fail to excrete acids into the urine, which causes a person's blood to remain too acidic. Without proper treatment, chronic acidity of the blood leads to growth retardation, kidney stones, bone disease, chronic kidney disease, and possibly total kidney failure. The body's cells use chemical reactions to carry out tasks such as turning food into energy and repairing tissue. These chemical reactions generate acids. Some acid in the blood is normal, but too much acid - acidosis - can disturb many bodily functions. Healthy kidneys help maintain acid-base balance by excreting acids into the urine and returning bicarbonate - an alkaline, or base, substance - to the blood. This reclaimed bicarbonate neutralizes much of the acid that is created when food is broken down in the body. The movement of substances like bicarbonate between the blood and structures in the kidneys is called transport.

Symptoms
Renal tubular acidosis (RTA) is usually asymptomatic. Severe electrolyte disturbances are rare but can be life threatening. Nephrolithiasis and nephrocalcinosis are possible, particularly with type 1 RTA.

Signs of ECF volume depletion may develop from urinary water loss accompanying electrolyte excretion in type 2 RTA.

People with type 1 or type 2 Renal tubular acidosis may show symptoms and signs of hypokalemia, including muscle weakness, hyporeflexia, and paralysis. Bony involvement (eg, bone pain and osteomalacia in adults and rickets in children) may occur in type 2 and sometimes in type 1 Renal tubular acidosis.

Diagnosis
To diagnose Renal tubular acidosis, doctors check the acid-base balance in blood and urine samples. If the blood is more acidic than it should be and the urine less acidic than it should be, Renal tubular acidosis may be the reason, but additional information is needed to rule out other causes. If RTA is the reason, additional information about the sodium, potassium, and chloride levels in the urine and the potassium level in the blood will help identify which type of Renal tubular acidosis a person has.

Treatment

• Varies by type
• Often alkali therapy
• Treatment of concomitant abnormalities related to potassium, calcium, and phosphate metabolism

Treatment consists of correction of pH and electrolyte balance with alkali therapy. Failure to treat Renal tubular acidosis in children slows growth. Alkaline agents such as sodium bicarbonate, potassium bicarbonate, or sodium citrate help achieve a relatively normal plasma bicarbonate concentration (22 to 24 mEq/L [22 to 24 mmol/L]). Potassium citrate can be substituted when persistent hypokalemia is present or, because sodium increases calcium excretion, when calcium calculi are present.

Vitamin D (eg, ergocalciferol 800 IU po once/day) and oral calcium supplements (elemental calcium 500 mg po tid, eg, as calcium carbonate, 1250 mg po tid) may also be needed to help reduce skeletal deformities resulting from osteomalacia or rickets.

Renal tubular acidosis Emerging Drugs Chapters

This segment of the Renal tubular acidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Renal tubular acidosis Emerging Drugs

ADV7103: AdvicenneADV7103 is an innovative prolonged-release granule combination of potassium citrate and potassium bicarbonate. In 2017, ADV7103 was granted orphan drug designation by the European Commission in the treatment of distal renal tubular acidosis (dRTA), a rare kidney disorder that occurs when the kidneys are unable to effectively remove the buildup of circulating acids in the blood. ADV7103 is currently in Phase III clinical trials for this indication in Europe, the United States and Canada, and a marketing application for the drug candidate has been submitted for centralized European review.

Renal tubular acidosis: Therapeutic Assessment

This segment of the report provides insights about the different Renal tubular acidosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Renal tubular acidosis

There are approx. 5+ key companies which are developing the therapies for Renal tubular acidosis. The companies which have their Renal tubular acidosis drug candidates in the mid to advanced stage, i.e. phase III include, Advicenne etc.

Phases

This report covers around 5+ products under different phases of clinical development like

• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Renal tubular acidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intramuscular
• Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Potassium compounds
• Electrolytes
• Citrates

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Renal tubular acidosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Renal tubular acidosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Renal tubular acidosis drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Renal tubular acidosis R&D. The therapies under development are focused on novel approaches to treat/improve Renal tubular acidosis.
• Advicenne has continued to prepare the next phase of its development, namely the European launch of its lead drug candidate, ADV7103, in the treatment of a first indication, distal renal tubular acidosis (dRTA), planned for the beginning of 2021.

Renal tubular acidosis Report Insights

• Renal tubular acidosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Renal tubular acidosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Renal tubular acidosis drugs?
• How many Renal tubular acidosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Renal tubular acidosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Renal tubular acidosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Renal tubular acidosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Advicenne

Key Products

• ADV7103